Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises A3P Biomedical in conjunction with directed share issue
Mandate

Vinge advises A3P Biomedical in conjunction with directed share issue

May 05, 2022 M&A

Vinge has advised A3P Biomedical in connection with an issue of shares amounting to SEK 400 million directed at Stena Sessan AB, TomEqt Private AB, Flerie Invest AB, Östersjöstiftelsen and Inbox Capital. A3P Biomedical specialises in advanced diagnostics of prostate cancer.

Vinge’s team primarily consisted of Johan Winnerblad, Rikard Lindahl, William Kåge, Lorin Arabi, Gabriel Chabo, Stojan Arnerstål, Arvid Axelryd and Olivia Belding.

Related

Vinge advises Aspo on its acquisition of Swed Handling

 Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

 Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

 Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024